PRAMEF17: A Potential Drug Target and Biomarker for the PRAME Family

Target Name: PRAMEF17

NCBI ID: G391004

PRAMEF17

Other Name(s): PRAME family member 17 | PRA17_HUMAN

PRAMEF17: A Potential Drug Target and Biomarker for the PRAME Family

The PRAME (PRamylgene-derived maintenance gene) family is a family of genes that encode for proteins involved in the immune response, inflammation, and cellular signaling pathways. PRAMEF17, also known as PRAMEF17, is a gene that has been identified as a potential drug target and biomarker for the PRAME family.

The PRAME family has been identified in various organisms, including humans, and is characterized by the presence of a specific gene that encodes a protein known as PRAME. PRAME is a transmembrane protein that plays a crucial role in the immune response by regulating the production of pro-inflammatory cytokines. The PRAME gene has been implicated in the development of various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases.

PRAMEF17, specifically, has been shown to be involved in the regulation of cellular signaling pathways, including the TGF-β pathway. The TGF-β pathway is a well-established pathway that is involved in the regulation of cell growth, differentiation, and inflammation. Studies have shown that PRAMEF17 is involved in the regulation of TGF-β signaling by binding to the TGF-β receptor. This binding allows PRAMEF17 to regulate the activity of the TGF-β receptor, thereby participating in the regulation of cellular processes such as cell growth, differentiation, and inflammation.

As a potential drug target, PRAMEF17 is of interest due to its involvement in the regulation of cellular signaling pathways. Many diseases, including autoimmune disorders and cancer, are characterized by the dysregulation of cellular signaling pathways. Therefore, targeting PRAMEF17 as a drug target may provide new insights into the pathogenesis of these diseases and may lead to the development of new therapeutic approaches.

In addition to its potential as a drug target, PRAMEF17 has also been identified as a potential biomarker for the PRAME family. The PRAME family has been implicated in the development of various diseases, including autoimmune disorders and cancer. Therefore, the detection and quantification of PRAMEF17 levels in tissues or fluids may be a useful biomarker for the diagnosis and monitoring of these diseases.

The detection and quantification of PRAMEF17 levels in tissues or fluids can be achieved using various techniques, including qRT-PCR, western blotting, and immunofluorescence. These techniques allow researchers to quantify the levels of PRAMEF17 in specific tissues or fluids and to study its localization and distribution. Detection of PRAMEF17 levels in tissues or fluids may be used to identify potential drug targets, monitor disease progression, and predict the response to therapeutic interventions.

In conclusion, PRAMEF17 is a gene that has been identified as a potential drug target and biomarker for the PRAME family. The regulation of cellular signaling pathways by PRAMEF17 is of interest due to its potential involvement in the development of various diseases. Further research is needed to fully understand the role of PRAMEF17 in the PRAME family and to develop effective therapeutic approaches based on this understanding.

Protein Name: PRAME Family Member 17

The "PRAMEF17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRAMEF17 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets